Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

XWELL Inc XWEL

XWELL, Inc. is a global health and wellness holding company. The Company operates through four segments: XpresTest, XpresSpa, Treat, and Naples Wax Center. The XpresTest segment provides diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public but has transitioned to the centers for disease control and prevention (CDC’s) bio-surveillance program. XpresTest’s HyperPointe business provides a range of service and support options for its customers, including technical support services and advanced services. The XpresSpa segment provides travelers premium spa services, including massage, nail and skin care, as well as spa and travel products. Treat segment is a wellness brand that provides access to wellness services for travelers at on-site centers. Naples Wax Center segment operates three high-performing locations with core products and service offerings from face and body waxing to a range of skincare and cosmetic products.


NDAQ:XWEL - Post by User

<< Previous
Bullboard Posts
Next >>
Post by Alfonsouon Apr 15, 2022 9:04am
127 Views
Post# 34606212

FSD Pharma Inc: Lucid MS Video

FSD Pharma Inc: Lucid MS Video


FSD Pharma is delighted to announce pre-clinical findings indicating the efficacy of Lucid-MS, its flagship medication candidate, in treating Multiple Sclerosis. Lucid-MS's therapeutic potential is an industry first, and we'd like to provide visual evidence of functional recovery in pre-clinical individuals in this video!

<< Previous
Bullboard Posts
Next >>